Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections
Article first published online: 16 JUL 2013
© 2013 The Societies and Wiley Publishing Asia Pty Ltd
Microbiology and Immunology
Volume 57, Issue 7, pages 527–535, July 2013
How to Cite
Günther, G. and Dreger, B. (2013), Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections. Microbiology and Immunology, 57: 527–535. doi: 10.1111/1348-0421.12060
- Issue published online: 16 JUL 2013
- Article first published online: 16 JUL 2013
- Accepted manuscript online: 22 APR 2013 06:40AM EST
- Manuscript Accepted: 14 APR 2013
- Manuscript Revised: 13 MAR 2013
- Manuscript Received: 9 JAN 2013
- Grifols Grifols Deutschland GmbH, Frankfurt, Germany
- 61992). The use of intravenous immunoglobulin in malignant disorders. In: Yap P. L. ed. Clinical Applications of Intravenous Immunoglobulin Therapy. Edinburgh: Churchill Livingstone., , (
- 8The European Agency for the Evaluation of Medicinal Products. (2010) Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) (EMA/CHMP/BPWP/94038/2007 rev. 3).
- 111994) Efficacy and safety of pasteurized intravenous 7S-immunoglobulin in primary and secondary immune deficiencies: results of a multicenter trial. 12th European Immunology Meeting Barcelona Abstract W50-15: 457., , , , , , (
- 19Instituto Grifols S.A. Flebogamma 5%: Summary of product characteristics available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000781/WC500023473.pdf. Last accessed: October 29, 2012.
- 20The European Agency for the Evaluation of Medicinal Products. (1999) Notice to Marketing Authorisation Holders. Pharmacovigilance Guidelines. CPMP/PhVWP/108/99.
- 212010). Internal Medicine. Cologne, Germany: Gerd Herold, Lulu. com.(
- 26US FDA. Guidance for Industry. Efficacy and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary immune deficiency. Last accessed: October 29, 2012. FDA 29-6-0008; Available from URL: http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm078526.pdf.